tetano
Editor, Senior Moderator
Vaccine. 2015 Jul 21. pii: S0264-410X(15)00970-6. doi: 10.1016/j.vaccine.2015.07.026. [Epub ahead of print]
[h=1]Recombinant H7 hemagglutinin forms subviral particles that protect mice and ferrets from challenge with H7N9 influenza virus.[/h] Pushko P[SUP]1[/SUP], Pujanauski LM[SUP]2[/SUP], Sun X[SUP]3[/SUP], Pearce M[SUP]3[/SUP], Hidajat R[SUP]4[/SUP], Kort T[SUP]4[/SUP], Schwartzman LM[SUP]2[/SUP], Tretyakova I[SUP]4[/SUP], Chunqing L[SUP]5[/SUP], Taubenberger JK[SUP]2[/SUP], Tumpey TM[SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] A novel avian-origin influenza A H7N9 virus emerged in China in 2013 and continues to cause sporadic human infections with mortality rates approaching 35%. Currently there are no approved human vaccines for H7N9 virus. Recombinant approaches including hemagglutinin (HA) and virus-like particles (VLPs) have resulted in experimental vaccines with advantageous safety and manufacturing characteristics. While high immunogenicity of VLP vaccines has been attributed to the native conformation of HA arranged in the regular repeated patterns within virus-like structures, there is limited data regarding molecular organization of HA within recombinant HA vaccine preparations. In this study, the full-length recombinant H7 protein (rH7) of A/Anhui/1/2013 (H7N9) virus was expressed in Sf9 cells. We showed that purified full-length rH7 retained functional ability to agglutinate red blood cells and formed oligomeric pleomorphic subviral particles (SVPs) of ∼20nm in diameter composed of approximately 10 HA0 molecules. No significant quantities of free monomeric HA0 were observed in rH7 preparation by size exclusion chromatography. Immunogenicity and protective efficacy of rH7 SVPs was confirmed in the mouse and ferret challenge models suggesting that SVPs can be used for vaccination against H7N9 virus.
Copyright ? 2015 Elsevier Ltd. All rights reserved.
[h=4]KEYWORDS:[/h] H7N9; Influenza; Influenza vaccine; VLP; Virus-like particles
PMID: 26207590 [PubMed - as supplied by publisher]
[h=1]Recombinant H7 hemagglutinin forms subviral particles that protect mice and ferrets from challenge with H7N9 influenza virus.[/h] Pushko P[SUP]1[/SUP], Pujanauski LM[SUP]2[/SUP], Sun X[SUP]3[/SUP], Pearce M[SUP]3[/SUP], Hidajat R[SUP]4[/SUP], Kort T[SUP]4[/SUP], Schwartzman LM[SUP]2[/SUP], Tretyakova I[SUP]4[/SUP], Chunqing L[SUP]5[/SUP], Taubenberger JK[SUP]2[/SUP], Tumpey TM[SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] A novel avian-origin influenza A H7N9 virus emerged in China in 2013 and continues to cause sporadic human infections with mortality rates approaching 35%. Currently there are no approved human vaccines for H7N9 virus. Recombinant approaches including hemagglutinin (HA) and virus-like particles (VLPs) have resulted in experimental vaccines with advantageous safety and manufacturing characteristics. While high immunogenicity of VLP vaccines has been attributed to the native conformation of HA arranged in the regular repeated patterns within virus-like structures, there is limited data regarding molecular organization of HA within recombinant HA vaccine preparations. In this study, the full-length recombinant H7 protein (rH7) of A/Anhui/1/2013 (H7N9) virus was expressed in Sf9 cells. We showed that purified full-length rH7 retained functional ability to agglutinate red blood cells and formed oligomeric pleomorphic subviral particles (SVPs) of ∼20nm in diameter composed of approximately 10 HA0 molecules. No significant quantities of free monomeric HA0 were observed in rH7 preparation by size exclusion chromatography. Immunogenicity and protective efficacy of rH7 SVPs was confirmed in the mouse and ferret challenge models suggesting that SVPs can be used for vaccination against H7N9 virus.
Copyright ? 2015 Elsevier Ltd. All rights reserved.
[h=4]KEYWORDS:[/h] H7N9; Influenza; Influenza vaccine; VLP; Virus-like particles
PMID: 26207590 [PubMed - as supplied by publisher]